STRADBIO Trademark

Trademark Overview

On Thursday, October 17, 2024, a trademark application was filed for STRADBIO with the United States Patent and Trademark Office. The USPTO has given the STRADBIO trademark a serial number of 98806662. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, July 22, 2025. This trademark is owned by StradBio, Inc.. The STRADBIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing medical and scientific research information in the field of treatment of oncological diseases, disorders, and conditions, and clinical trials and post-market trials related to treatment of oncological diseases, disorders, and conditions; consulting services in the field of research and development of treatments, pharmaceuticals, and therapeutics for oncological diseases, disorders, and conditions; cancer treatment research and development; providing medical and scientific research information in the field of treatment of inflammatory diseases, disorders, and conditions, and clinical trials and post-market trials related to treatment of inflammatory diseases, disorders, and conditions; consulting services in the field of research and development of treatments, pharmaceuticals, and therapeutics for inflammatory diseases, disorders, and conditions; research in the field of bioengineering; research in the field of molecular engineering; medical and clinical research and developme...
stradbio

General Information

Serial Number98806662
Word MarkSTRADBIO
Filing DateThursday, October 17, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, July 22, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 27, 2025

Trademark Statements

Pseudo MarkSTRAD BIO
Goods and ServicesProviding medical and scientific research information in the field of treatment of oncological diseases, disorders, and conditions, and clinical trials and post-market trials related to treatment of oncological diseases, disorders, and conditions; consulting services in the field of research and development of treatments, pharmaceuticals, and therapeutics for oncological diseases, disorders, and conditions; cancer treatment research and development; providing medical and scientific research information in the field of treatment of inflammatory diseases, disorders, and conditions, and clinical trials and post-market trials related to treatment of inflammatory diseases, disorders, and conditions; consulting services in the field of research and development of treatments, pharmaceuticals, and therapeutics for inflammatory diseases, disorders, and conditions; research in the field of bioengineering; research in the field of molecular engineering; medical and clinical research and development for others in the field of cellular therapy; consulting services in the field of cellular therapy for scientific or research purposes, disease model systems, and drug discovery and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, October 17, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameStradBio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWashington, DC 20004
Party NameStradBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20004

Trademark Events

Event DateEvent Description
Thursday, October 17, 2024NEW APPLICATION ENTERED
Friday, April 18, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 21, 2025ASSIGNED TO EXAMINER
Wednesday, April 23, 2025EXAMINERS AMENDMENT -WRITTEN
Wednesday, April 23, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 21, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, April 23, 2025EXAMINERS AMENDMENT E-MAILED
Wednesday, April 23, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 23, 2025EXAMINER'S AMENDMENT ENTERED
Tuesday, May 27, 2025PUBLISHED FOR OPPOSITION
Tuesday, July 22, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 27, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

stradbio research field disorders conditions diseases treatment trials clinical development oncological